Leap Therapeutics (LPTX) News Today

$2.49

+0.03 (+1.22%)

(As of 11/29/2023 ET)

Today's Range: $2.43
▼
$2.65
50-Day Range: $1.30
▼
$2.86
52-Week Range: $1.24
▼
$10.20

Volume: 118,092 shs
Average Volume: 186,620 shs
Market Capitalization: $63.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.30

Source

Source	Headline
	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference finance.yahoo.com - November 21 at 7:52 AM
	Leap Therapeutics (NASDAQ:LPTX) Price Target Cut to $12.00 by Analysts at Mizuho americanbankingnews.com - November 21 at 3:42 AM
	Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know markets.businessinsider.com - November 14 at 2:08 PM
	Leap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2023 Financial Results finanznachrichten.de - November 13 at 9:31 AM
	Recap: Leap Therapeutics Q3 Earnings benzinga.com - November 13 at 9:31 AM
	Leap Therapeutics Reports Third Quarter 2023 Financial Results finance.yahoo.com - November 13 at 9:31 AM
	Leap Therapeutics to Participate at Upcoming Investor Conferences finance.yahoo.com - September 5 at 6:06 PM
	HC Wainwright & Co. Maintains Leap Therapeutics (LPTX) Buy Recommendation msn.com - August 15 at 6:09 PM
	Baird Maintains Leap Therapeutics (LPTX) Outperform Recommendation msn.com - August 15 at 6:09 PM
	Leap Therapeutics (LPTX) Receives a Buy from H.C. Wainwright markets.businessinsider.com - August 15 at 7:59 AM
	Leap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2023 Financial Results finanznachrichten.de - August 14 at 4:53 PM
	Leap Therapeutics Reports Second Quarter 2023 Financial Results finance.yahoo.com - August 14 at 4:53 PM
	Raymond James Maintains Leap Therapeutics (LPTX) Outperform Recommendation msn.com - July 14 at 12:41 AM
	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients finance.yahoo.com - July 12 at 9:07 AM
	Leap Therapeutics (LPTX) Price Target Increased by 876.00% to 24.89 msn.com - July 6 at 11:33 PM
	Leap Therapeutics (LPTX) Receives a Buy from Raymond James markets.businessinsider.com - June 23 at 12:27 PM
	Leap Therapeutics (NASDAQ:LPTX) Given New $17.00 Price Target at Raymond James marketbeat.com - June 23 at 9:08 AM
	8-K: LEAP THERAPEUTICS, INC. marketwatch.com - June 22 at 3:37 PM
	Leap Therapeutics, Inc.: Leap Therapeutics Announces Reverse Stock Split finanznachrichten.de - June 21 at 8:14 AM
	Leap Therapeutics Announces Reverse Stock Split finance.yahoo.com - June 20 at 2:45 PM
	Robert W. Baird Sticks to Their Buy Rating for Leap Therapeutics (LPTX) markets.businessinsider.com - May 29 at 3:34 PM
	Leap Therapeutics (LPTX) Receives a Buy from Mizuho Securities markets.businessinsider.com - May 26 at 2:13 AM
	HC Wainwright & Co. Reiterates Leap Therapeutics (LPTX) Buy Recommendation msn.com - May 16 at 9:31 PM
	H.C. Wainwright Sticks to Its Buy Rating for Leap Therapeutics (LPTX) markets.businessinsider.com - May 16 at 9:33 AM
	Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Leap Therapeutics (LPTX) and Jasper Therapeutics (JSPR) markets.businessinsider.com - May 15 at 3:04 PM
	Leap Therapeutics Reports First Quarter 2023 Financial Results finance.yahoo.com - May 15 at 10:03 AM
	Mizuho Reiterates Leap Therapeutics (LPTX) Buy Recommendation msn.com - April 13 at 5:56 PM
	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients finance.yahoo.com - April 12 at 10:16 AM
	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely finance.yahoo.com - April 4 at 12:58 PM
	What 5 Analyst Ratings Have To Say About Leap Therapeutics markets.businessinsider.com - March 27 at 1:39 PM
	Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX) markets.businessinsider.com - March 24 at 2:39 PM
	Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results finanznachrichten.de - March 24 at 9:39 AM
	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results prnewswire.com - March 24 at 7:11 AM
	Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX) markets.businessinsider.com - March 20 at 2:23 PM
	Mizuho Securities Sticks to Its Buy Rating for Leap Therapeutics (LPTX) markets.businessinsider.com - March 16 at 11:16 PM
	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 finance.yahoo.com - March 16 at 6:16 PM
	Leap Therapeutics, Inc. (LPTX) uk.finance.yahoo.com - March 16 at 1:49 AM
	Leap Therapeutics (NASDAQ:LPTX) PT Lowered to $3.00 marketbeat.com - January 27 at 7:41 AM
	SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations benzinga.com - January 25 at 2:36 PM
	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition finance.yahoo.com - January 25 at 9:36 AM
	LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders businesswire.com - January 24 at 6:54 PM
	HC Wainwright Weighs in on Leap Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:LPTX) marketbeat.com - January 20 at 8:42 AM
	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout wsj.com - January 19 at 2:39 PM
	HC Wainwright & Co. Maintains Buy Rating for Leap Therapeutics: Here's What You Need To Know msn.com - January 18 at 1:47 PM
	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference finance.yahoo.com - November 21 at 9:30 AM
	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) finance.yahoo.com - November 16 at 7:51 PM
	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting finance.yahoo.com - November 7 at 9:40 AM
	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - October 26 at 8:48 AM
	LPTX Leap Therapeutics, Inc. seekingalpha.com - October 19 at 10:37 PM
	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer finance.yahoo.com - October 12 at 8:54 AM

Get Leap Therapeutics News Delivered to You Automatically

LPTX Media Mentions By Week

LPTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LPTX
News Sentiment
▼
1.89

0.74
▲
Average
Medical
News Sentiment

LPTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LPTX Articles
This Week
▼
1

1
▲
LPTX Articles
Average Week

Get Leap Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:LPTX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Leap Therapeutics (LPTX) News Today

LPTX Media Mentions By Week

LPTX Media Sentiment

LPTX News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info